PhorMed Inc.

About PhorMed Inc.

PhorMed, Inc. is a biopharmaceutical company focused on developing and commercializing cell repair therapies and immunotherapies, such as RP-323, to treat life-threatening diseases including cancer, neurological disorders, and inflammatory lung conditions like Acute Respiratory Distress Syndrome (ARDS). Their mission is to redefine treatment by restoring damaged cells, reducing harmful inflammation, and changing the standard of care to bring hope to patients in need.

Products & Services

RP-323:A targeted cell repair therapy and immunotherapy designed to promote the reduction of inflammation and help the body repair itself, used for treating neurological diseases, cancer, and inflammatory lung disorders like ARDS.

Specialties

Cell Repair Therapies Immunotherapy Inflammation Reduction Neurological Diseases Cancer Treatment Inflammatory Lung Disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Crowdfunding T: - FT: Equity Crowdfunding	A: 5000000 MR: - FA: 5 million FAN: 5000000	D: 2024-02-22 FD: 2024-02-22	1 investors

Equity Crowdfunding Latest

2024-02-22

$5.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard L. Chang

Chief Scientific Advisor / Inventor

B

Ben Chang

CEO / Director

C

Carole A. Salvador

Secretary, Treasurer, and Human Resources Director

C

C. Scott Naylor

Chief Medical Officer

S

Steven J. Davis

ESQ, Legal Counsel

J

Joseph Huffman

CPA, Finance Director

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

PhorMed Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised